Copyright
©2013 Baishideng Publishing Group Co.
World J Gastroenterol. Mar 7, 2013; 19(9): 1387-1395
Published online Mar 7, 2013. doi: 10.3748/wjg.v19.i9.1387
Published online Mar 7, 2013. doi: 10.3748/wjg.v19.i9.1387
Table 4 The average ribavirin dose during 2 different time-points among inosine triphosphate pyrophosphatase CC and non CC genotypes
| During first 12 wk | 12-48 wk of treatment | |||||
| Total | CC | CA + AA | Total | CC | CA + AA | |
| No. of patients | 102 | 93 | 9 | 91 | 82 | 9 |
| RBV dose (mg/wk), mean ± SD | 947 ± 151.4 | 936 ± 148.3 | 1059 ± 144.1 | 943 ± 153.2 | 930.5 ± 149.6 | 1059 ± 144.1 |
| P value | 0.035 | 0.029 | ||||
- Citation: Ahmed WH, Furusyo N, Zaky S, Sharaf Eldin A, Aboalam H, Ogawa E, Murata M, Hayashi J. Pre-treatment role of inosine triphosphate pyrophosphatase polymorphism for predicting anemia in Egyptian hepatitis C virus patients. World J Gastroenterol 2013; 19(9): 1387-1395
- URL: https://www.wjgnet.com/1007-9327/full/v19/i9/1387.htm
- DOI: https://dx.doi.org/10.3748/wjg.v19.i9.1387